编号：2022-008 证券代码：002286 证券简称：保龄宝 保龄宝生物股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

| --- | --- | --- | --- | |------------------|--------------------------------------------|----------------------------------------------------------------------|------------------------------| | | | | | | 证券简称：保龄宝 | 证券代码： | 002286 | 公告编号： 2022-074 | | | | 保龄宝生物股份有限公司 | | | | 关于参加山东辖区上市公司 | 2022 | 年度投资者网上集 | | | | 体接待日活动的公告 | | | | | 公司董事会及全体成员保证公告内容的真实、准确和完整，不存在虚假记录、 | | | | 误导性陈述或者重大遗漏。 | | | | | | 为进一步加强与广大投资者的沟通交流，保龄宝生物股份有限公司（以下简 | | | 称 " 公司 " | ）将于 2022年11月16 日（星期三） | 14:00 | — 16:00 参加由山东证监局、 | | | | ...

证券代码： 002286 证券简称：保龄宝 保龄宝生物股份有限公司投资者关系活动记录表 编号：2022-010 | --- | --- | --- | |----------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

保龄宝生物股份有限公司 2022 年第三季度报告 证券代码：002286 证券简称：保龄宝 公告编号：2022-067 保龄宝生物股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 4.受国际、国内疫情反复，大宗商品价格上涨，消费低迷，部分产品竞争加剧等不利因素影响，报告期内，公司业绩出 现波动，剔除赤藓糖醇产品价格波动影响，公司盈利能力仍保持稳定增长。公司正围绕高端化，功能化、差异化，数字 化四化目标，实现转型升级。 在收入增加战略方面，一是通过创新解决方案引领，扩大新市场，新产品和新客户的收入规模；二是通过强化与现 有客户的关系而增加现有客户的销售，包括组合销售，多种产品和服务，为客户提供一体化解决方案。 在 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥1,382,780,708.23, representing a 9.61% increase compared to ¥1,261,506,868.39 in the same period last year [23]. - The net profit attributable to shareholders was ¥90,752,005.19, a 40.60% increase from ¥64,545,330.64 year-on-year [23]. - The net profit after deducting non-recurring gains and losses was ¥85,368,968.55, up 68.96% from ¥50,525,838.51 in the previous year [23]. - The basic earnings per share increased by 41.18% to ¥0.24 from ¥0.17 in the same period last year [23]. - The company achieved a total revenue of 1.383 billion CNY, representing a year-on-year growth of 9.61% [57]. - The net profit attributable to shareholders reached 90.75 million CNY, marking a year-on-year increase of 40.60% [57]. - The gross profit margin for the first half of 2022 was reported at 42.76%, indicating strong operational efficiency [76]. - The company's net profit margin for the first half of 2022 was 5.8%, indicating a stable profitability level [199]. Cash Flow and Liquidity - The company reported a net cash flow from operating activities of -¥78,219,756.47, a significant decrease of 136.74% compared to ¥212,883,308.91 in the previous year [23]. - The company's cash and cash equivalents decreased by 378.01%, totaling ¥-73,535,747.06, primarily due to increased payments for raw materials and project costs [58]. - The company's cash and cash equivalents decreased from 585,440,493.40 CNY at the beginning of the year to 375,154,746.34 CNY by June 30, 2022, a decline of approximately 36% [179]. - The ending balance of cash and cash equivalents was 333,354,746.34 CNY as of the end of the first half of 2022, compared to 271,502,006.73 CNY at the end of the first half of 2021 [194]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,009,685,058.70, a slight decrease of 0.64% from ¥3,028,995,791.18 at the end of the previous year [23]. - The company's long-term borrowings increased by 1,087.84% to ¥231,955,198.89, primarily due to new project financing [60]. - Current liabilities totaled ¥830,706,883.68, a decrease from ¥1,119,839,668.47 at the start of the year, indicating a reduction of approximately 25.8% [181]. - The total liabilities at the end of the reporting period were 1.8 billion yuan, representing a 3.7% increase from the previous year [200]. Business Operations and Strategy - The company continues to focus on enzyme engineering and fermentation engineering, maintaining a strong position in the functional sugar industry with over 90 different specifications of functional food ingredients [30]. - The company has developed a comprehensive product structure covering high, medium, and low categories of functional sugars, including functional oligosaccharides, dietary fibers, and functional sugar alcohols [32]. - The company is a strategic partner for many food and beverage enterprises and is a key player in the national "Public Nutrition Improvement Microecology Project" [30]. - The company has established a complete industrial chain for the production of erythritol, which has gained wide recognition in both domestic and international markets [87]. - The company is focusing on high-tech, high-margin, and high-value-added products, with traditional products like glucose syrup and maltodextrin seeing steady margin improvements [56]. Research and Development - The company is actively investing in R&D for new technologies, with a budget allocation of 1,880 million for innovation initiatives [76]. - The company plans to enhance its research and development investment in functional sugars to improve product quality and application solutions [87]. - The company has implemented a digital upgrade in its production processes, with its "medicinal sugar workshop" recognized as a digital workshop by the Shandong Provincial Department of Industry and Information Technology [131]. Environmental and Social Responsibility - The company has maintained stable operation of its environmental protection facilities, achieving compliance with pollutant discharge standards [100]. - The company has implemented measures to reduce carbon emissions, although specific results were not detailed in the report [111]. - The company emphasizes its mission of "creating a better life through biotechnology," focusing on economic, social, and ecological benefits [112]. - The company has actively participated in social responsibility initiatives, promoting green development and sustainable practices [112]. Risk Management - The management has highlighted potential risks and corresponding mitigation strategies in the report [6]. - The company has implemented a hedging strategy to mitigate raw material price fluctuations, particularly for corn and corn starch, which are subject to significant market volatility [84]. - The company aims to reduce the impact of raw material price increases on profit margins by improving production processes and exploring new procurement models [84]. Shareholder and Governance - The company has not engaged in any major asset or equity sales during the reporting period, maintaining its asset structure [82]. - The company has not utilized any fundraising during the reporting period, indicating stable financial management [81]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period, indicating financial integrity [136].

Financial Performance - The company reported a significant profit increase driven by the rapid launch of new projects in the biological sector, particularly with erythritol and allulose, aligning with changing consumer trends[144]. - The company achieved a revenue of 2.765 billion yuan in 2021, representing a year-on-year growth of 34.58%[96]. - The net profit attributable to shareholders reached 202 million yuan, a significant increase of 304.28% compared to the previous year[96]. - The company's operating revenue for 2021 was ¥2,764,976,972.69, representing a 34.58% increase compared to ¥2,054,578,268.02 in 2020[21]. - The net profit attributable to shareholders for 2021 was ¥201,579,400.15, a significant increase of 304.28% from ¥49,861,881.27 in 2020[21]. - The net profit after deducting non-recurring gains and losses was ¥164,369,745.11, reflecting a 353.28% increase compared to ¥36,262,261.21 in 2020[21]. - The company reported a quarterly operating revenue of ¥815,251,756.04 in Q3 2021, the highest among the four quarters[25]. - The company achieved a net profit of ¥184,030,967.09 for the year 2021, with a total distributable profit of ¥510,103,521.31 after accounting for legal reserves and previous undistributed profits[197]. Dividend Distribution - The company plans to distribute a cash dividend of 0.60 RMB per 10 shares to all shareholders, based on a total of 371,911,900 shares[5]. - The cash dividend distribution plan for 2021 is set at ¥0.60 per 10 shares (including tax), totaling ¥22,314,714.00, which represents 100% of the profit distribution[197]. - The company has not proposed any cash dividend distribution plan for the current reporting period despite having positive distributable profits[197]. Research and Development - The company is investing in research and development of new products and technologies to enhance its competitive edge in the market[12]. - The company achieved a research and development investment of ¥100,613,062.55 in 2021, representing a 58.05% increase from ¥63,659,830.52 in 2020[118]. - R&D investment accounted for 3.64% of total revenue in 2021, up from 3.10% in the previous year, indicating a focus on innovation[118]. - The number of R&D personnel increased to 153 in 2021, a rise of 4.79% from 146 in 2020[117]. - The company completed key technology research for the green preparation of resistant dextrin, aiming to enhance production efficiency and reduce costs[114]. - The company is developing new products such as lactulose to expand its existing product line[114]. - The company has established key technologies for the production of high-end modified starches, aimed at increasing market share in international markets[116]. - The company is conducting research on the high-value utilization of lactose, aiming to enhance product variety and market competitiveness[116]. Market Position and Strategy - The company is focused on expanding its product offerings in functional foods, which are designed to enhance health without treating diseases[12]. - The company has outlined its future development outlook, which includes strategies for market expansion and potential mergers and acquisitions[5]. - The company operates in the functional sugar industry, focusing on enzyme engineering and fermentation technology, with a diverse product range including functional sugars and dietary fibers[30]. - The company has a strong market presence with a diversified product structure and a robust marketing network, achieving significant market share in various segments of functional sugars[75]. - The company is positioned as the only full-category functional sugar manufacturer in the domestic market, leveraging its core technology and full industry chain advantages[81]. - The company is actively pursuing capacity cooperation and expanding its import and OEM business to achieve high-quality growth during the reporting period[97]. - The company aims to enhance its market presence by exploring new applications and developing new downstream industry clients to reduce dependency on large customers[147]. Governance and Management - The company emphasizes the importance of accurate and complete financial reporting, with key executives confirming the integrity of the annual report[4]. - The report includes a comprehensive overview of the company's governance and social responsibility initiatives, indicating a commitment to ethical practices[7]. - The company has established a comprehensive human resources management system, ensuring independent personnel management[159]. - The company has a clear and independent organizational structure, with strict adherence to corporate governance[160]. - The company has undergone significant changes in its supervisory board, with new members being elected to enhance governance[166]. - The company is committed to maintaining a robust governance structure through regular board elections and appointments[166]. Risk Management - The management discussion highlights potential risks the company may face in future operations, urging investors to be aware of investment risks[5]. - The company emphasizes risk management strategies to mitigate raw material price fluctuations, including futures hedging and improving production processes[146]. - The company has established a hedging management system to control risks associated with futures trading and ensure compliance with relevant regulations[141]. - The report highlighted a focus on risk management strategies to mitigate potential losses from market fluctuations[133]. Product Development and Innovation - The company has developed and industrialized new products including allulose, precision prebiotics, and low-viscosity maltotetraose, further enhancing its product portfolio[76]. - The company is positioned to leverage its first-mover advantage in the health industry, focusing on a core health industry system based on biological ingredients[141]. - The company has completed the industrialization of resistant starch production, which is expected to meet customer demands and enhance market competitiveness[116]. - The company is in the process of developing a new strain of erythritol to meet strong market demand, which will drive rapid growth[116]. Financial Management - The company operates independent financial management, with a dedicated finance department and accounting system[160]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 10.86 million CNY[181]. - The highest remuneration was received by the General Manager, who earned 1.71 million CNY[182]. - The company adheres to a remuneration policy that links income levels to company performance and individual performance assessments[181]. - The company has implemented a strategic procurement decision-making process to maximize profits while managing raw material costs[96].

Financial Performance - The company's revenue for Q1 2022 was CNY 657,767,709.68, representing an increase of 18.54% compared to CNY 554,900,133.35 in the same period last year[3] - Net profit attributable to shareholders reached CNY 42,723,700.71, a significant increase of 383.94% from CNY 8,828,328.31 in the previous year[3] - The net profit after deducting non-recurring gains and losses was CNY 39,345,780.14, up 585.62% from CNY 5,738,709.86 year-on-year[3] - Basic and diluted earnings per share were both CNY 0.11, reflecting a 450.00% increase from CNY 0.02 in the previous year[3] - Total operating revenue for the current period reached ¥657,767,709.68, an increase from ¥554,900,133.35 in the previous period[16] - Net profit for the current period was ¥42,723,700.71, compared to ¥8,828,328.31 in the previous period, reflecting a significant increase[18] - The total comprehensive income for the current period was ¥29,784,691.74, compared to ¥7,975,787.69 in the previous period[19] - The company reported a basic and diluted earnings per share of ¥0.11, up from ¥0.02 in the previous period[19] Cash Flow and Liquidity - The company's cash flow from operating activities showed a net outflow of CNY 136,105,401.07, a decrease of 392.90% compared to a net inflow of CNY 46,468,413.92 in the same period last year[3] - The company reported a net cash flow from operating activities of -¥136,105,401.07, a decline from a positive cash flow of ¥46,468,413.92 in the prior period[22] - Cash inflow from operating activities was ¥750,203,392.85, an increase from ¥633,224,145.16 in the previous period[20] - The company's cash and cash equivalents decreased by 35.58% to CNY 377,116,103.66 due to increased payments for raw materials[6] - Cash and cash equivalents at the end of the period totaled ¥346,066,103.66, compared to ¥267,784,546.92 at the end of the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,914,407,619.13, down 3.78% from CNY 3,028,995,791.18 at the end of the previous year[3] - Total assets decreased to ¥2,914,407,619.13 from ¥3,028,995,791.18, a decline of approximately 3.8%[15] - Total liabilities decreased to ¥1,066,584,375.80 from ¥1,215,764,108.09, a reduction of about 12.3%[14] - The company's retained earnings increased to ¥573,412,669.35 from ¥530,688,968.64, showing an increase of approximately 8%[15] - The total equity attributable to the parent company was ¥1,847,823,243.33, up from ¥1,813,231,683.09, reflecting a growth of about 1.9%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period was 40,936[9] - The top shareholder, Beijing Yongyu Investment Management Co., Ltd., holds 12.71% of shares, totaling 47,273,390 shares[10] Expenses - The company reported a significant increase in sales expenses by 33.35% to CNY 9,186,432.63, mainly due to higher salaries for sales personnel[6] - The company incurred research and development expenses of ¥1,879,430.38, slightly up from ¥1,760,718.02 in the previous period[16] Borrowings and Financing - Long-term borrowings increased by 792.83% to CNY 174,347,543.03, attributed to project financing and medium to long-term loans[6] - The company reported a short-term loan balance of ¥420,419,471.56, an increase from ¥369,178,398.38 at the beginning of the year[14] - The company raised ¥340,111,933.86 from financing activities, compared to ¥133,000,000.00 in the previous period[22] Accounts Receivable and Inventory - Accounts receivable increased to ¥313,411,937.67 from ¥284,293,463.48, reflecting a growth of approximately 10%[13] - Inventory at the end of the reporting period was ¥340,650,286.07, compared to ¥285,092,988.97 at the beginning of the year, indicating an increase of about 19.5%[13]

证券代码：002286 证券简称：保龄宝 公告编号：2021-101 保龄宝生物股份有限公司 关于参加山东辖区上市公司2021年度投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 为进一步加强与广大投资者的沟通交流，保龄宝生物股份有限公司（以下简 称"公司"）将参加由山东证监局、山东上市公司协会联合举办并由深圳市全景 网络有限公司承办的"山东辖区上市公司 2021 年度投资者网上集体接待日活 动"，现将有关事项公告如下： 本次集体接待日活动将采取网络远程的方式举行，投资者可以登录"全景 • 路演天下"网站（http://rs.p5w.net）参与本次活动。活动时间为 2021 年 11 月 16 日（星期二）14:00 至 16:00。 届时公司副总经理、董事会秘书张国刚先生、证券事务代表张锋锋先生将通 过网络在线交流形式与投资者进行沟通交流，欢迎广大投资者积极参与。 特此公告。 保龄宝生物股份有限公司董事会 2021 年 11 月 12 日 ...

Financial Performance - The company's revenue for Q3 2021 reached ¥815,251,756.04, representing a 55.00% increase compared to the same period last year[2] - Net profit attributable to shareholders was ¥95,782,796.24, a significant increase of 831.96% year-on-year[2] - The net profit excluding non-recurring gains and losses was ¥86,191,564.65, up 1,328.19% from the previous year[2] - Basic earnings per share were ¥0.26, reflecting a 766.67% increase compared to the same period last year[2] - The company reported a 34.64% increase in revenue for the year-to-date period, totaling ¥2,076,758,624.43[6] - The company achieved a revenue of RMB 2.077 billion in the first three quarters of 2021, representing a year-on-year growth of 34.64%[12] - The net profit attributable to shareholders reached RMB 160 million, marking a significant year-on-year increase of 198.72%[12] - Total operating revenue for the third quarter reached CNY 2,076,758,624.43, a 34.7% increase from CNY 1,542,499,534.07 in the same period last year[18] - Net profit for the quarter was CNY 160,328,126.88, representing a significant increase of 198.5% compared to CNY 53,670,976.82 in the previous year[19] - Earnings per share (EPS) for the quarter was CNY 0.43, compared to CNY 0.15 in the same quarter last year[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,912,555,946.91, an increase of 11.35% from the end of the previous year[2] - The total assets as of September 30, 2021, amounted to RMB 2.913 billion, up from RMB 2.616 billion at the end of 2020[15] - The total current liabilities increased to RMB 1.093 billion from RMB 956.41 million at the end of 2020, reflecting changes in financial obligations[15] - The total liabilities increased to CNY 1,174,228,723.20, up from CNY 1,016,367,838.48 year-over-year[19] - The total equity attributable to shareholders reached CNY 1,738,327,223.71, an increase from CNY 1,599,359,459.63 in the previous year[19] Cash Flow - Cash flow from operating activities decreased by 41.81% to ¥288,318,344.61, primarily due to increased payments for raw materials[7] - The net cash inflow from operating activities for Q3 2021 was CNY 288,318,344.61, a decrease of 41.9% compared to CNY 495,469,857.08 in Q3 2020[23] - Cash generated from operating activities was CNY 2,174,896,584.93, compared to CNY 1,702,625,963.25 in the previous year[22] - The company reported a total cash outflow from operating activities of CNY 2,028,628,173.25, compared to CNY 1,462,911,286.15 in the previous year[23] - The company’s net cash and cash equivalents decreased by 36.81% to ¥96,056,679.50, attributed to increased payments for raw materials and investments[7] - The cash and cash equivalents at the end of Q3 2021 stood at CNY 341,107,813.30, up from CNY 326,509,842.87 at the end of Q3 2020[24] Research and Development - Research and development expenses increased by 107.42% to ¥10,829,505.78, driven by intensified efforts in new product and technology development[7] - Research and development expenses for the quarter were CNY 10,829,505.78, a 107.5% increase from CNY 5,221,166.56 in the same period last year[19] Shareholder Information - The top shareholder, Beijing Yongyu Investment Management Co., holds 12.80% of the shares, with 8 million shares under judicial freeze[10] Operational Strategy - The company is focusing on enhancing its manufacturing capabilities and optimizing production lines to reduce costs and expand capacity[11] - The company is responding to the growing demand for functional sugar products driven by health trends, particularly in prebiotics and dietary fibers[11] - The company has implemented a new pricing management mechanism to improve profitability based on market insights[11] Other Financial Information - Total operating costs amounted to CNY 1,912,547,277.13, up 27.8% from CNY 1,495,677,599.50 year-over-year[18] - The company reported a total comprehensive income of CNY 159,419,234.30 for the quarter, compared to CNY 49,198,415.55 in the same period last year[20] - Deferred income increased to CNY 61,852,697.56 from CNY 49,169,751.91 year-over-year[19] - Total cash inflow from investing activities was CNY 158,070,081.73, significantly up from CNY 6,388,261.02 in the previous year[23] - The net cash outflow from investing activities was CNY 148,539,179.07, compared to a smaller outflow of CNY 27,034,737.33 in Q3 2020[23] - Cash inflow from financing activities totaled CNY 303,277,000.00, an increase from CNY 286,000,000.00 in the same quarter last year[24] - The net cash outflow from financing activities was CNY 43,017,940.20, improving from a net outflow of CNY 312,384,188.51 in Q3 2020[24] - The company did not require adjustments to the beginning balance sheet items due to the new leasing standards implemented in 2021[25] - The Q3 2021 report was not audited, indicating that the figures may be subject to change upon final audit[26]

Financial Performance - The company reported a revenue of 1.5 billion yuan for the first half of 2021, representing a year-on-year increase of 20%[1]. - The company has set a revenue guidance of 3 billion yuan for the full year 2021, indicating a growth target of 25%[3]. - The company's operating revenue for the first half of 2021 was approximately ¥1.26 billion, representing a 24.10% increase compared to the same period last year[24]. - The net profit attributable to shareholders for the same period was approximately ¥64.55 million, an increase of 48.74% year-on-year[24]. - The net profit after deducting non-recurring gains and losses was approximately ¥50.53 million, reflecting a 26.82% increase compared to the previous year[24]. - Basic and diluted earnings per share increased by 41.67% to ¥0.17 per share[24]. - The company achieved total revenue of 1.26 billion yuan, a year-on-year increase of 24.10%[47]. - The net profit attributable to shareholders reached 64.55 million yuan, up 48.74% compared to the previous year[47]. - The total operating revenue for the first half of 2021 was CNY 1,261,506,868.39, representing a 24.10% increase compared to CNY 1,016,516,605.44 in the same period last year[50]. - The net profit for the first half of 2021 was ¥64,545,330.64, representing a 48.8% increase from ¥43,393,357.49 in the first half of 2020[149]. User Growth and Market Expansion - User data showed an increase in active users by 15% compared to the previous year, reaching 2 million active users[2]. - Market expansion efforts have led to a 10% increase in market share in the health food sector[6]. - New product launches in the functional food segment contributed to 30% of total sales in the first half of 2021[4]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence[7]. - A strategic partnership with a leading health organization was established to promote product awareness and education[8]. - The company plans to enhance its online sales channels, targeting a 50% increase in e-commerce revenue by the end of 2021[9]. Research and Development - The company is investing 200 million yuan in R&D for new technologies aimed at enhancing product efficacy and safety[5]. - The company focuses on R&D innovation and has established a comprehensive innovation system to support its growth in the health industry[42]. - The company has developed a new generation of functional sweeteners, allulose, which has significant applications in food, health, and medical fields, and has been recognized in international markets[35]. - Research and development expenses for the first half of 2021 were ¥4,244,192.90, up from ¥3,635,836.39 in the same period last year, indicating a growth of 16.8%[147]. Financial Management and Investments - The company received government subsidies amounting to approximately ¥6.44 million, which were included in the current period's profit[28]. - The company reported a decrease in cash flow from operating activities, indicating potential challenges in maintaining liquidity[24]. - The company has implemented a systematic pricing and adjustment mechanism to manage product pricing effectively, ensuring profit margins are maintained despite fluctuations in raw material costs[37]. - The company has utilized financial tools such as futures hedging to lock in order profits and manage raw material price trends effectively[38]. - The company reported an investment income of ¥7,141,660.10, significantly higher than ¥3,591,312.78 in the first half of 2020[147]. Environmental and Social Responsibility - The company reported a total COD discharge of 726.839 tons per year, with an average concentration of 77.2 mg/l, well below the regulatory limit of 300 mg/l[83]. - The average ammonia nitrogen discharge was 84.798 tons per year, with an average concentration of 3.55 mg/l, also below the limit of 25 mg/l[83]. - The company has maintained stable operation of its environmental protection facilities, with no environmental violations or accidents reported in the first half of 2021[83]. - The company actively participates in social responsibility initiatives and maintains good relationships with various public welfare organizations[93]. Corporate Governance and Compliance - The company has established a robust internal management and control system, ensuring compliance with corporate governance and investor protection measures[90]. - The company has not engaged in any significant related party transactions or non-operating fund occupation during the reporting period[96][97]. - The company has not reported any major litigation or arbitration matters during the reporting period[102]. - The company adheres to the accounting standards set by the Ministry of Finance and the China Securities Regulatory Commission, ensuring the accuracy of its financial reporting[182]. Asset and Liability Management - Total assets at the end of the reporting period were approximately ¥2.88 billion, a 10.08% increase from the end of the previous year[24]. - Total liabilities reached CNY 1,237,735,044.13, up from CNY 1,016,367,838.48, representing an increase of about 21.7%[141]. - The company's equity attributable to shareholders rose to CNY 1,641,572,023.30 from CNY 1,599,359,459.63, showing a growth of approximately 2.6%[142]. - The total owner's equity at the end of the first half of 2021 was approximately 1,631.81 million, compared to 1,595.56 million at the end of the previous year, reflecting an increase of 36.25 million[170].